Schering completes divestment of radiopharmaceutical business

Published: 9-May-2006


Schering Group's French subsidiary Schering SAS has completed the transfer of the radiopharmaceutical business of CIS bio international to a consortium formed by the Belgian companies Ion Beam Applications (IBA) and the Institut National des Radioelements (IRE), in the wake of the agreement signed in February.

As part of the transaction, the consortium has acquired Schering's current radiopharmaceutical business while Schering continues to focus on the promising innovative diagnostic fields of Magnetic Resonance Imaging, Computer Tomography and optical as well as molecular imaging.

You may also like